Alberta Bergamo

List of Publications by Year
in descending order

67 papers	5,473 citations	168829 31 h-index	120465 65 g-index
70 all docs	70 docs citations	70 times ranked	5410 citing authors

#	Article	IF	Citations
1	Long-term resveratrol treatment improves the capillarization in the skeletal muscles of ageing C57BL/6J mice. International Journal of Food Sciences and Nutrition, 2021, 72, 37-44.	1.3	12
2	Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data. Journal of Autoimmunity, 2021, 125, 102742.	3.0	42
3	Lysozyme-Induced Transcriptional Regulation of TNF-Î± Pathway Genes in Cells of the Monocyte Lineage. International Journal of Molecular Sciences, 2019, 20, 5502.	1.8	21
4	Long Non-Coding RNA GAS5 and Intestinal MMP2 and MMP9 Expression: A Translational Study in Pediatric Patients with IBD. International Journal of Molecular Sciences, 2019, 20, 5280.	1.8	24
5	The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions. Coordination Chemistry Reviews, 2018, 360, 17-33.	9.5	94
6	Chemical and Molecular Approach to Tumor Metastases. International Journal of Molecular Sciences, 2018, 19, 843.	1.8	3
7	Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A. Journal of Inorganic Biochemistry, 2017, 168, 90-97.	1.5	10
8	Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties. International Journal of Molecular Sciences, 2016, 17, 1254.	1.8	11
9	Inhibition of adhesion, migration and of Î±5Î²1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A. Journal of Inorganic Biochemistry, 2016, 160, 225-235.	1.5	30
10	Phototoxic Activity and DNA Interactions of Waterâ€Soluble Porphyrins and Their Rhenium(I) Conjugates. ChemMedChem, 2015, 10, 1901-1914.	1.6	30
11	Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through Î±5Î²1 Integrin. Journal of Cellular Biochemistry, 2015, 116, 2385-2396.	1.2	28
12	Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-Î²1 in the metastatic process. Journal of Biological Inorganic Chemistry, 2015, 20, 1163-1173.	1.1	22
13	Linking the future of anticancer metal-complexes to the therapy of tumour metastases. Chemical Society Reviews, 2015, 44, 8818-8835.	18.7	190
14	RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A. Metallomics, 2015, 7, 1439-1450.	1.0	15
15	Preclinical combination therapy of the investigational drug NAMI-A+ with doxorubicin for mammary cancer. Investigational New Drugs, 2015, 33, 53-63.	1.2	32
16	Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo. Journal of Membrane Biology, 2014, 247, 1239-1251.	1.0	12
17	Towards Matched Pairs of Porphyrinâ€“Re^I/^{99m}Tc^I Conjugates that Combine Photodynamic Activity with Fluorescence and Radio Imaging. ChemMedChem, 2014, 9, 1231-1237.	1.6	30
18	Novel water-soluble 99mTc(I)/Re(I)-porphyrin conjugates as potential multimodal agents for molecular imaging. Journal of Inorganic Biochemistry, 2013, 122, 57-65.	1.5	34

#	Article	IF	Citations
19	Photolabile Ru^{II} Halfâ€Sandwich Complexes Suitable for Developing â€œCagedâ€•Compounds: Chemical Investigation and Unexpected Dinuclear Species with Bridging Diamine Ligands. European Journal of Inorganic Chemistry, 2013, 2013, 4743-4753.	1.0	7
20	CDK1 Hyperphosphorylation Maintenance Drives the Time-course of G2-M Cell Cycle Arrest after Short Treatment with NAMI-A in Kb Cells. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 949-958.	0.9	10
21	Synthesis and characterization of a diruthenium(II,III)â€“ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives. Polyhedron, 2012, 42, 175-181.	1.0	30
22	New half sandwich Ru(ii) coordination compounds for anticancer activity. Dalton Transactions, 2012, 41, 7358.	1.6	47
23	Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs. Dalton Transactions, 2012, 41, 8226.	1.6	94
24	Approaching tumour therapy beyond platinum drugs. Journal of Inorganic Biochemistry, 2012, 106, 90-99.	1.5	468
25	New half sandwich-type Ru(ii) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity. Dalton Transactions, 2011, 40, 9533.	1.6	28
26	Metal-based antitumour drugs in the post-genomic era: what comes next?. Dalton Transactions, 2011, 40, 9069.	1.6	220
27	Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Transactions, 2011, 40, 7817.	1.6	384
28	Synthesis, characterization and tumor cell growth inhibition of new trans platinum complexes with phosphane derivatives. Polyhedron, 2011, 30, 1646-1650.	1.0	23
29	In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model. Journal of Inorganic Biochemistry, 2010, 104, 79-86.	1.5	161
30	Rutheniumâ^'Porphyrin Conjugates with Cytotoxic and Phototoxic Antitumor Activity. Journal of Medicinal Chemistry, 2010, 53, 4678-4690.	2.9	120
31	Ruthenium Drugs for Cancer Chemotherapy: An Ongoing Challenge to Treat Solid Tumours. , 2009, , 57-66.		8
32	Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation. Journal of Biological Inorganic Chemistry, 2008, 13, 511-520.	1.1	37
33	Influence of the anionic ligands on the anticancer activity of Ru(II)â€“dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors. Journal of Inorganic Biochemistry, 2008, 102, 606-617.	1.5	19
34	Half-sandwich RuII[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: Preparation, structural characterization and in vitro cytotoxic activity. Journal of Inorganic Biochemistry, 2008, 102, 1120-1133.	1.5	43
35	Tuning the hydrophobicity of ruthenium(ii)â€“arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Transactions, 2007, , 5065.	1.6	131
36	Novel platinum pyridinehydroxamic acid complexes: Synthesis, characterisation, X-ray crystallographic study and nitric oxide related properties. Polyhedron, 2007, 26, 4697-4706.	1.0	21

#	Article	IF	Citations
37	Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds. Organometallics, 2006, 25, 756-765.	1.1	154
38	The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. International Journal of Oncology, 2006, 29, 261-8.	1.4	12
39	Is the Aromatic Fragment of Piano-Stool Ruthenium Compounds an Essential Feature for Anticancer Activity? The Development of New RuII-[9]aneS3 Analogues. European Journal of Inorganic Chemistry, 2005, 2005, 3423-3434.	1.0	114
40	Platinum(II) Complexes with Antitumoral/Antiviral Aromatic Heterocycles:Â Effect of Glutathione upon in Vitro Cell Growth Inhibition. Journal of Medicinal Chemistry, 2005, 48, 3364-3371.	2.9	37
41	In Vitro and in Vivo Evaluation of Ruthenium(II)â^'Arene PTA Complexes. Journal of Medicinal Chemistry, 2005, 48, 4161-4171.	2.9	723
42	Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion. International Journal of Oncology, 2004, 24, 373.	1.4	1
43	Ruthenium Antimetastatic Agents. Current Topics in Medicinal Chemistry, 2004, 4, 1525-1535.	1.0	452
44	Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir. Journal of Inorganic Biochemistry, 2004, 98, 1385-1390.	1.5	30
45	Synthesis, characterization and biological activity of copper complexes with pyridoxal thiosemicarbazone derivatives. X-ray crystal structure of three dimeric complexes. Journal of Inorganic Biochemistry, 2004, 98, 301-312.	1.5	117
46	Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives. Journal of Inorganic Biochemistry, 2004, 98, 393-401.	1.5	47
47	Synthesis and Chemicalâ^'Pharmacological Characterization of the Antimetastatic NAMI-A-Type Ru(III) Complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-Dimethyl[1,2,4]triazolo[1,5-a]pyrimidine). Journal of Medicinal Chemistry, 2004, 47, 1110-1121.	2.9	118
48	Ruthenium Anticancer Drugs. , 2004, , 323-351.		84
49	Ruthenium anticancer drugs. Metal Ions in Biological Systems, 2004, 42, 323-51.	0.4	14
50	Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin. Investigational New Drugs, 2003, 21, 401-411.	1.2	95
51	Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl4(Im)(DMSO)], (I) and of the orange form of [(DMSO)2H][trans-IrCl4(DMSO)2], (II), complexes. Journal of Inorganic Biochemistry, 2003, 95, 37-46.	1.5	52
52	Distinct Effects of Dinuclear Ruthenium(III) Complexes on Cell Proliferation and on Cell Cycle Regulation in Human and Murine Tumor Cell Lines. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 725-732.	1.3	25
53	Synthesis, catalytic properties and biological activity of new water soluble ruthenium cyclopentadienyl PTA complexes [(C5R5)RuCl(PTA)2] (R = H, Me; PTA =) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 107 Td (1,3,5-tri 31P{1H}, 1H, 13C NMR characterisation and elemental analysis of 1 and 2. See http://www.rsc.org/suppdata/cc/b2/b210102e/. Chemical Communications, 2003, , 264-265.	2.2	143
54	Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clinical Cancer Research, 2003, 9, 1898-905.	3.2	184

#	Article	IF	Citations
55	Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells. Cancer Chemotherapy and Pharmacology, 2002, 50, 405-411.	1.1	31
56	Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. British Journal of Cancer, 2002, 86, 993-998.	2.9	123
57	Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity. International Journal of Oncology, 2002, 21, 1331-8.	1.4	19
58	Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. Anti-Cancer Drugs, 2000, 11, 665-672.	0.7	53
59	Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[{trans-RuCl4(Me2SO)}2(Î¼-L)] (L=ditopic, non-chelating aromatic N-ligand). A preliminary investigation. Journal of Inorganic Biochemistry, 2000, 79, 173-177.	1.5	20
60	Sulfoxide Ruthenium Complexes: Non-Toxic Tools for the Selective Treatment of Solid Tumour Metastases. , 1999, , 143-169.		34
61	Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: The crystal structure of [ImH][trans-RhCl4(Im)2] (Im=imidazole). Inorganica Chimica Acta, 1998, 273, 62-71.	1.2	62
62	Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry. Chemico-Biological Interactions, 1998, 113, 51-64.	1.7	12
63	CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. British Journal of Haematology, 1997, 97, 652-655.	1.2	42
64	Treatment of residual metastases with Na[trans-RuCl4(DMSO)Im] and ruthenium uptake by tumor cells. Anti-Cancer Drugs, 1996, 7, 697-702.	0.7	31
65	Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti-metastatic ruthenium complex. , 1996, 68, 60-66.		68
66	Synthetic Thymic Fraction 5: Effects of High Dose Administration on Circulating Lymphocytes in Patients. Cancer Biotherapy and Radiopharmaceuticals, 1996, 11, 105-111.	0.7	2
67	Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition. Chemico-Biological Interactions, 1995, 95, 109-126.	1.7	80